110 related articles for article (PubMed ID: 31341009)
1. ELP3 Acetyltransferase is phosphorylated and regulated by the oncogenic anaplastic lymphoma kinase (ALK).
Li MT; Liang JY; Sun YP; Jin J; Xiong Y; Guan KL; Yuan HX
Biochem J; 2019 Aug; 476(15):2239-2254. PubMed ID: 31341009
[TBL] [Abstract][Full Text] [Related]
2. The tyrosine 343 residue of nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) is important for its interaction with SHP1, a cytoplasmic tyrosine phosphatase with tumor suppressor functions.
Hegazy SA; Wang P; Anand M; Ingham RJ; Gelebart P; Lai R
J Biol Chem; 2010 Jun; 285(26):19813-20. PubMed ID: 20424160
[TBL] [Abstract][Full Text] [Related]
3. The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration.
Voena C; Conte C; Ambrogio C; Boeri Erba E; Boccalatte F; Mohammed S; Jensen ON; Palestro G; Inghirami G; Chiarle R
Cancer Res; 2007 May; 67(9):4278-86. PubMed ID: 17483340
[TBL] [Abstract][Full Text] [Related]
4. Elp3 drives Wnt-dependent tumor initiation and regeneration in the intestine.
Ladang A; Rapino F; Heukamp LC; Tharun L; Shostak K; Hermand D; Delaunay S; Klevernic I; Jiang Z; Jacques N; Jamart D; Migeot V; Florin A; Göktuna S; Malgrange B; Sansom OJ; Nguyen L; Büttner R; Close P; Chariot A
J Exp Med; 2015 Nov; 212(12):2057-75. PubMed ID: 26527802
[TBL] [Abstract][Full Text] [Related]
5. SUMOylation Confers Posttranslational Stability on NPM-ALK Oncogenic Protein.
Vishwamitra D; Curry CV; Shi P; Alkan S; Amin HM
Neoplasia; 2015 Sep; 17(9):742-754. PubMed ID: 26476082
[TBL] [Abstract][Full Text] [Related]
6. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma.
Zhang Q; Raghunath PN; Xue L; Majewski M; Carpentieri DF; Odum N; Morris S; Skorski T; Wasik MA
J Immunol; 2002 Jan; 168(1):466-74. PubMed ID: 11751994
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic kinase NPM/ALK induces expression of HIF1α mRNA.
Marzec M; Liu X; Wong W; Yang Y; Pasha T; Kantekure K; Zhang P; Woetmann A; Cheng M; Odum N; Wasik MA
Oncogene; 2011 Mar; 30(11):1372-8. PubMed ID: 21102525
[TBL] [Abstract][Full Text] [Related]
8. The histone acetyltransferase Elp3 plays in active role in the control of synaptic bouton expansion and sleep in Drosophila.
Singh N; Lorbeck MT; Zervos A; Zimmerman J; Elefant F
J Neurochem; 2010 Oct; 115(2):493-504. PubMed ID: 20626565
[TBL] [Abstract][Full Text] [Related]
9. Targeting oncogenic ALK: a promising strategy for cancer treatment.
Grande E; Bolós MV; Arriola E
Mol Cancer Ther; 2011 Apr; 10(4):569-79. PubMed ID: 21474455
[TBL] [Abstract][Full Text] [Related]
10. Elongator promotes the migration and invasion of hepatocellular carcinoma cell by the phosphorylation of AKT.
Xu Y; Zhou W; Ji Y; Shen J; Zhu X; Yu H; Guo J; Pang Z; Wei W
Int J Biol Sci; 2018; 14(5):518-530. PubMed ID: 29805303
[TBL] [Abstract][Full Text] [Related]
11. Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3.
Kasprzycka M; Marzec M; Liu X; Zhang Q; Wasik MA
Proc Natl Acad Sci U S A; 2006 Jun; 103(26):9964-9. PubMed ID: 16766651
[TBL] [Abstract][Full Text] [Related]
12. NPM-ALK mediates phosphorylation of MSH2 at tyrosine 238, creating a functional deficiency in MSH2 and the loss of mismatch repair.
Bone KM; Wang P; Wu F; Wu C; Li L; Bacani JT; Andrew SE; Lai R
Blood Cancer J; 2015 May; 5(5):e311. PubMed ID: 25978431
[TBL] [Abstract][Full Text] [Related]
13. Model of inhibition of the NPM-ALK kinase activity by herbimycin A.
Turturro F; Arnold MD; Frist AY; Pulford K
Clin Cancer Res; 2002 Jan; 8(1):240-5. PubMed ID: 11801565
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
[TBL] [Abstract][Full Text] [Related]
15. Analysis of gene expression profile of TPM3-ALK positive anaplastic large cell lymphoma reveals overlapping and unique patterns with that of NPM-ALK positive anaplastic large cell lymphoma.
Bohling SD; Jenson SD; Crockett DK; Schumacher JA; Elenitoba-Johnson KS; Lim MS
Leuk Res; 2008 Mar; 32(3):383-93. PubMed ID: 17720243
[TBL] [Abstract][Full Text] [Related]
16. The NPM-ALK oncoprotein abrogates CD30 signaling and constitutive NF-kappaB activation in anaplastic large cell lymphoma.
Horie R; Watanabe M; Ishida T; Koiwa T; Aizawa S; Itoh K; Higashihara M; Kadin ME; Watanabe T
Cancer Cell; 2004 Apr; 5(4):353-64. PubMed ID: 15093542
[TBL] [Abstract][Full Text] [Related]
17. Serine phosphorylation of NPM-ALK, which is dependent on the auto-activation of the kinase activation loop, contributes to its oncogenic potential.
Wang P; Wu F; Zhang J; McMullen T; Young LC; Ingham RJ; Li L; Lai R
Carcinogenesis; 2011 Feb; 32(2):146-53. PubMed ID: 21045017
[TBL] [Abstract][Full Text] [Related]
18. Biochemical detection of novel anaplastic lymphoma kinase proteins in tissue sections of anaplastic large cell lymphoma.
Pulford K; Falini B; Cordell J; Rosenwald A; Ott G; Müller-Hermelink HK; MacLennan KA; Lamant L; Carbone A; Campo E; Mason DY
Am J Pathol; 1999 Jun; 154(6):1657-63. PubMed ID: 10362790
[TBL] [Abstract][Full Text] [Related]
19. Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy.
Li R; Morris SW
Med Res Rev; 2008 May; 28(3):372-412. PubMed ID: 17694547
[TBL] [Abstract][Full Text] [Related]
20. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.
Bonvini P; Gastaldi T; Falini B; Rosolen A
Cancer Res; 2002 Mar; 62(5):1559-66. PubMed ID: 11888936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
